ALY688

ALY688 is a synthetic decapeptide and first-in-class adiponectin receptor agonist derived from the active site of human globular adiponectin. It acts as a potent and specific mimetic of adiponectin by activating multiple adiponectin signaling pathways—primarily through AdipoR1—with downstream effects including activation of AMP-activated protein kinase (AMPK) and p38 mitogen-activated protein kinase. ALY688 has demonstrated anti-inflammatory, anti-fibrotic, pro-metabolic, and insulin-sensitizing properties in preclinical models. It reduces inflammation and fibrosis in tissues such as liver, heart, muscle, and eye; improves insulin sensitivity; promotes fatty acid oxidation; suppresses pro-inflammatory gene expression; and inhibits cancer cell growth in AdipoR-positive lines. The drug is being developed for several indications including dry eye disease (in Phase 3 clinical trials), metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes mellitus (preclinical/early clinical), muscular dystrophy (preclinical), atherosclerosis (preclinical), and potentially other fibrotic or inflammatory diseases[1][2][3][4][5][6].

Other names

aly688aly-688aly 688adp355adp-355adp 355